Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INS37217 Nasal Spray in Perennial Allergic Rhinitis
NCT00210015Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2002
- Primary completion
- Apr 2003
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in perennial allergic rhinitis (PAR) comparing INS37217 with Placebo (2 arms). Primary endpoint: Total Nasal Symptom Score. Started Dec 2002; status: completed.
02
Drugs
denufosol tetrasodium
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT00210015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00210015.